Ovarian and endometrial cancers with CCNE1-amplification are often resistant to standard treatment. Here, the authors identify that CCNE1-amplified gynecological cancer is sensitive to combined PKMYT1 and ATR inhibition via CDK1 activation, resulting in premature mitosis, DNA damage, cell apoptosis and reduced tumour growth and metastasis.
- Haineng Xu
- Erin George
- Fiona Simpkins